Trulieve Cannabis Q2 Earnings Call Highlights
Trulieve Cannabis reported Q2 revenue of $271 million, including $222 million medical-only revenue. Adjusted EBITDA was $98 million (36% margin). Operating cash flow was $53 million and free cash flow $32 million, with $325 million cash and $289 million debt. The company authorized a $50 million share repurchase program in June. It expects Q3 medical-only revenue comparable to $222 million and raised capex to $95 million.
How this was made
The 30-second read
Why it matters
Traders can update models using the disclosed Q2 financial metrics, the Georgia program changes (THC cap removal, expanded qualifying conditions, product availability), the early July traffic surge and sellout, and the Texas license conversion and retail pipeline. The guidance update is the key decision input: Q3 medical-only revenue comparable to $222M and gross margin comparable to 63%, with full-year operating cash flow cut to at least $225M from $250M and capex raised to $95M from $85M due to deconsolidation.
Market read
Guidance and state-level operational catalysts provide actionable inputs for near-term positioning in medical cannabis equities, with the cash flow versus capex tradeoff as the main risk.
What to watch
The article notes no Q2 share repurchases despite a June authorization, and it does not quantify the deconsolidation magnitude, leaving uncertainty around the sustainability of cash flow and the timing of capex payback.
Background
The piece summarizes Trulieve’s Q2 earnings call, focusing on cash flow, growth initiatives in Georgia and Texas, and updated Q3 and full-year guidance.
Ticker impact
Trulieve reported Q2 results and outlined Georgia and Texas expansion plans, including a Q3 revenue and margin outlook plus updated full-year cash flow and capex guidance.
Moderately positive bias, but guidance mix (lower operating cash flow, higher capex) may cap upside until deconsolidation impact clarity improves.
The article contains multiple concrete operating metrics (revenue, EBITDA margin, cash/free cash flow) and specific state-level growth catalysts (Georgia THC cap removal, patient count, pharmacy distribution; Texas retail pipeline). The most decision-relevant items for traders are the Q3 comparable revenue and gross margin expectations and the full-year operating cash flow reduction alongside capex increase.
Market effects
Adds incremental read-through on US medical cannabis demand drivers (state program liberalization, pharmacy distribution) and on operator capex intensity versus cash generation.
Highlights Georgia as a near-term growth engine and Texas as a longer buildout, potentially shifting attention and capital allocation within the medical cannabis peer group.
Limited, as the catalysts are US state-specific and not tied to global macro or cross-border regulation.
Counterpoint
The Georgia momentum (traffic tripled, sold out of flower) could be temporary if cultivation ramp delays or if product mix changes pressure margins, while deconsolidation is already forcing a lower operating cash flow outlook.
Key entities
- companyTrulieve Cannabis
Vertically integrated medical cannabis operator providing Q2 results and state expansion updates for Georgia and Texas, plus updated guidance.
- regulationGeorgia medical marijuana program
Program changes effective July 1, including removal of a THC cap and expanded qualifying conditions and product types.
- regulationTexas Compassionate Use Program
Trulieve holds a conditional license and is working to convert it into a final license while building production and a retail pipeline.
